论文部分内容阅读
目前在临床应用的血管紧张素转换酶抑制剂有巯甲丙脯酸(captopril)、苯酯丙脯酸(enalapril)和ramipril等,其中巯甲丙脯酸为直接有效的含巯基药物,后二者则为不含巯基的前体药物,须经肝脏代谢转化后方显效。这类药物抑制血管紧张素转换酶的活性,阻滞血管紧张素Ⅰ的形成,从而产生护血管作用,临床上主要用于高血压和充血性心衰的治疗。血管紧张素Ⅱ有广泛的生理活性,对肾脏呈直接和间接作用,当其合成受阻抑时,肾功能将受到明显影响。
Angiotensin-converting enzyme inhibitors currently used clinically are captopril, enalapril and ramipril, among which captopril is a direct and effective thiol-containing drug and the latter two Those who are not mercapto-containing prodrugs, metabolism by the liver after the conversion was effective. These drugs inhibit the activity of angiotensin-converting enzyme, blocking the formation of angiotensin I, resulting in the role of blood vessels, clinically used mainly for the treatment of hypertension and congestive heart failure. Angiotensin II has a wide range of physiological activities, the kidneys were direct and indirect effects, when its synthesis was inhibited, renal function will be significantly affected.